Liraglutide Tracker App
Track Victoza (T2D) and Saxenda (Obesity) in Shotlee
Liraglutide is available in two formulations: Victoza (1.2–1.8 mg daily for type 2 diabetes, FDA approved 2010) and Saxenda (3.0 mg daily for obesity, FDA approved 2014). It is the longest-established GLP-1 receptor agonist with over 15 years of real-world safety data. The LEADER trial demonstrated cardiovascular mortality benefit, and the SCALE trials showed 8.4% mean weight loss. Track either protocol in Shotlee.
What Is Liraglutide?
Liraglutide is a GLP-1 receptor agonist with 97% sequence homology to native human GLP-1. Developed by Novo Nordisk, it was the first long-acting GLP-1 agonist to receive FDA approval (January 2010 as Victoza for T2D, December 2014 as Saxenda for obesity). It achieves a 24-hour half-life through a C-16 fatty acid chain that promotes non-covalent albumin binding, enabling once-daily dosing.
The same molecule is used at two different dose levels for two distinct indications. As Victoza (1.2–1.8 mg), it targets glycaemic control in type 2 diabetes — demonstrated in the LEADER trial to reduce cardiovascular death by 22% in high-risk patients. As Saxenda (3.0 mg), the higher dose engages hypothalamic appetite circuits more intensely, driving the 8.4% mean weight loss seen in the SCALE-Obesity trial.
While largely succeeded by semaglutide (Ozempic/Wegovy) for efficacy, liraglutide remains widely prescribed globally due to its long safety record, established reimbursement pathways, and continued availability in markets where semaglutide supply is constrained.
Liraglutide Doses: Victoza vs Saxenda
Initiation dose for both Victoza and Saxenda. Not therapeutic — designed to improve GI tolerability.
Primary therapeutic dose for T2D. Adequate glycaemic control for most patients. LEADER trial dose.
Higher Victoza dose for additional HbA1c reduction. Assess response before escalating.
Full obesity dose via 4-step weekly escalation (0.6→1.2→1.8→2.4→3.0). SCALE-Obesity maintenance dose.
Clinical Trial Highlights
What to Track in Shotlee
Whether you are on Victoza for T2D or Saxenda for weight loss, Shotlee tracks both protocols with equal depth.
Protocol FAQs
Both are liraglutide by Novo Nordisk. Victoza (1.2–1.8 mg) is for type 2 diabetes — it improves HbA1c and has proven cardiovascular mortality benefit (LEADER). Saxenda (3.0 mg) is for obesity/weight management — it produces 8.4% mean weight loss (SCALE). The dose is the primary difference.
Yes. Liraglutide has a 15+ year post-marketing safety record that semaglutide cannot yet match. It remains a first-line option in many countries due to cost, reimbursement, and supply availability. Some patients also prefer the daily injection schedule for incremental titration control.
Semaglutide (Wegovy 2.4 mg weekly) outperforms Saxenda (liraglutide 3.0 mg daily) for weight loss: 14.9% vs 8.4% mean loss. However, both are clinically meaningful vs diet alone. Track your personal results in Shotlee to quantify your individual response.
LEADER was a cardiovascular outcomes trial with 9,340 high-CV-risk type 2 diabetes patients, median follow-up 3.8 years. Liraglutide reduced 3-point MACE by 13% and CV death by 22% vs placebo — the first GLP-1 to show CV mortality superiority. It established liraglutide as a cardioprotective T2D medication.
Use Shotlee to log each daily injection (dose, time, injection site), weekly body weight, HbA1c from clinic visits, blood pressure, and any side effects. The app keeps your full medication history accessible for review with your prescriber.
